Theravance Biopharma (TBPH) Cost of Revenue (2014 - 2018)

Theravance Biopharma (TBPH) has 5 years of Cost of Revenue data on file, last reported at $826000.0 in Q1 2018.

• Cost of Revenue for Q1 2018 came in at $826000.0, up 46.19% year-over-year; the trailing twelve-month figure through Mar 2018 was $6.3 million (up 134.65% YoY), and the FY2017 annual result was $6.0 million, up 108.36% from the prior year.
• Cost of Revenue eased to $826000.0 in Q1 2018 per TBPH's latest filing, from $3.1 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $3.2 million in Q4 2014 and troughed at $188000.0 in Q1 2014.
• A 5-year average of $1.1 million and a median of $638000.0 in 2016 frame the typical range for Cost of Revenue.
• The sharpest annual moves came in 2016 and 2017: Cost of Revenue sank 64.2% in 2016, then surged 196.69% in 2017.
• A 5-year view of Cost of Revenue shows it stood at $3.2 million in 2014, then retreated by 0.65% to $3.2 million in 2015, then slumped by 64.2% to $1.1 million in 2016, then jumped by 171.9% to $3.1 million in 2017, then plunged by 73.49% to $826000.0 in 2018.
• Business Quant data shows TBPH's Cost of Revenue at $826000.0 in Q1 2018, $3.1 million in Q4 2017, and $985000.0 in Q3 2017.